Incompatibility between fasting and postprandial plasma glucose in patients with Cushing's syndrome.

It is shown that glucocorticoids have discordant effects on plasma glucose concentration through their effects on hepatic glycogen deposition, gluconeogenesis and peripheral insulin resistance. Cushing's syndrome caused by cortisol overproduction is frequently accompanied with diabetes mellitus, but fasting plasma glucose (FPG) and post-glucose load plasma glucose levels are not examined in patients with Cushing's syndrome. The aim of this study was to investigate FPG, HbA1c and oral glucose tolerance test (OGTT) 2-h PG and their relationship in patients with Cushing's syndrome, in comparison with control subjects. Sixteen patients with Cushing's syndrome (ACTH-dependent 31%, ACTH-independent 69% and diabetes mellitus 50%) and 64 controls (32 patients with type 2 diabetes mellitus and 32 non-diabetic subjects matched for age, sex and BMI) were enrolled in this study. HbA1c and FPG in the patients with Cushing's syndrome were not different from the controls, whereas the FPG/HbA1c ratio was significantly lower in the patients with Cushing's syndrome than the controls. OGTT 2-h PG was significantly higher in the non-diabetic patients with Cushing's syndrome than the non-diabetic controls, while HbA1c was not different between both groups and FPG was significantly lower in the patients with Cushing's syndrome than the controls. HOMA-β but not HOMA-R was significantly higher in the patients with Cushing's syndrome than the controls. In conclusion, FPG was rather lower in the patients with Cushing's syndrome than the controls. Postprandial PG or post-glucose loaded PG, but not FPG, is useful to evaluate the abnormality of glucose metabolism in patients with Cushing's syndrome.

[1]  V. Guarnotta,et al.  Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? , 2014, European journal of endocrinology.

[2]  S. Kihara,et al.  The elderly. , 2014, Journal of atherosclerosis and thrombosis.

[3]  Malcolm D. Smith,et al.  Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. , 2012, Rheumatology.

[4]  T. Sanke,et al.  International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values , 2012, Diabetology International.

[5]  T. Yoshimoto,et al.  Clinical outcome of subclinical Cushing's syndrome after surgical and conservative treatment , 2011, Hypertension Research.

[6]  P. Frith,et al.  Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. , 2011, The Journal of clinical endocrinology and metabolism.

[7]  T. Ogihara,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) , 2009, Hypertension Research.

[8]  T. Ogihara,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)—Chapter 2 , 2009, Hypertension Research.

[9]  G. Arnaldi,et al.  High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines , 2004, Clinical endocrinology.

[10]  C. Bhagat Diagnosis and Complications of Cushing's Syndrome: a Consensus Statement. , 2004 .

[11]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[12]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[13]  J. Etxabe,et al.  Morbidity and mortality in Cushing's disease: an epidemiological approach , 1994, Clinical endocrinology.

[14]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[15]  H. Segal,et al.  Glucocorticoid control of the liver glycogen synthetase-activating system. , 1969, The Journal of biological chemistry.

[16]  D. Orth.,et al.  THE ADRENAL CORTEX , 1948 .

[17]  K. Shimamoto The Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 (JSH2014) , 2014 .

[18]  N. Krone,et al.  CHAPTER 15 – The Adrenal Cortex , 2011 .

[19]  Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. , 1999, Lancet.

[20]  L. Mandarino,et al.  Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. , 1982, The Journal of clinical endocrinology and metabolism.